関連する実験動画

Updated: Sep 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

ジェムシタビンとベバシズマブの併用療法の有効性

Yasunori Yoshino^1,2, Akiko Furusawa³, Katsuhiko Nara⁴

¹Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

|August 31, 2025

まとめ

プラチナ耐性卵巣透明細胞癌 (PR- OCCC) の第一線治療としてゲムシタビン (GEM) は生存率の改善を示しています. ベバシズマブ (Bev) の併用療法もPR- OCCC患者にとって有望な治療法である.

科学分野:

腫瘍学
婦人科腫瘍学
化学療法研究

背景:

プラチナ耐性卵巣透明細胞癌 (PR- OCCC) は,標準化学療法に対する耐性および患者の予後不良により,重大な臨床的課題となっています.
臨床前および臨床データは,ゲムシタビン (GEM) がOCCCに対して顕著な有効性を示すことを示唆しています.
ベバシズマブ (Bev) は,この患者集団における化学療法の有効性を高めると推測されています.

研究の目的:

プラチナ耐性卵巣透明細胞癌 (PR- OCCC) の第一線治療としてゲムシタビン (GEM) の有効性を評価する.
PR- OCCCにおけるベバシズマブ (Bev) 併用療法による治療結果の影響を評価する.
PR-OCCC治療への反応におけるAT豊富な相互作用領域1A (ARID1A) のタンパク質発現の役割を調査する.

主な方法:

PR- OCCC患者130人を対象とした多中心の,遡及的なコホート研究.
ベバシズマブ (Bev) による単剤化学療法を受けた患者の治療結果の分析
治療スケジュールとARID1Aタンパク質発現状態に関連した全生存期 (OS) と治療失敗までの時間 (TTF) の評価

主要な成果:

GEMを初期療法として投与された患者は,他の薬剤で治療された患者と比較して, signicantly better overall survival (OS) を示した (平均OS: 15. 2 vs 11. 0ヶ月; p=. 032).
ベバシズマブ (Bev) 併用療法により,化学療法単独療法と比較して治療失敗までの期間 (TTF) が有意に改善され (6. 6 vs.
ARID1Aタンパク質発現の減少は,全体的な患者コホートやGEM第一線サブグループにおいてOSに有意な影響を及ぼさなかった.

結論:

プラチナ抵抗性卵巣透明細胞癌 (PR- OCCC) が診断された患者の予後を向上させる第一線療法として,ジェムシタビン (GEM) が用いられる.
ベバシズマブ (Bev) を併用した組み合わせ治療は,PR- OCCCに対する潜在的に効果的な治療戦略です.
ARID1A状態は,この設定での治療応答の予測バイオマーカーではないようです.

キーワード:

AT豊富な相互作用領域 1A (ARID1A)ベバシズマブジェムシタビン卵巣の透明細胞がんプラチナ抵抗

さらに関連する動画

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

関連する概念動画

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.